Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 CASI Acquires Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339 | Contract Pharma

What are you searching for?

Sign in
Breaking News

CASI Acquires Rights to Cleave Therapeutics’ VCP/P97 Inhibitor CB-5339

CASI will assume responsibility of the U.S. CB-5339 investigational NDA.

By: Anthony Vecchione

CASI Pharmaceuticals executed an Assignment Agreement with Cleave Therapeutics, Inc., under which CASI obtained all rights and global intellectual property related to CB-5339, a novel VCP/p97 inhibitor, as well as all remaining CB-5339 drug substance and drug product. Additionally, CASI will assume responsibility of the CB-5339 Investigational New Drug application.

CB-5339 is an oral, second-generation, small molecule valosin-containing protein (VCP)/p97 inhibitor, designed to disrupt protein homeostasis, DNA damage response and other cellular stress pathways. In a Phase 1 clinical trial in patients with acute myeloid leukemia and myelodysplastic syndrome, the drug was well tolerated in 55 patients and demonstrated signs of clinical activity. Two patients remain on CB-5339 under compassionate use protocols at two leading U.S. cancer centers.

Wei-Wu He, Ph.D., CASI’s Chairman and CEO said, “CB-5339 is a first in class small molecule drug candidate that represents a promising opportunity to selectively target VCP/p97 in various malignancies. We are encouraged by the early clinical data in the phase 1 study of CB-5339 in patients with AML and MDS. CB-5339 is a complementary addition to our growing portfolio of approved and investigational therapies in oncology. 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics